Skip to main content

Table 8 Discordance of hormonal receptor and HER2 status between primary and metastatic samples (only in patients with rebiopsies and with diagnoses confirmed by pathologist; n = 80)

From: Factors that predict recurrence later than 5 years after initial treatment in operable breast cancer

  Change of HR and/or HER2 status
Early recurrence (n = 40) Late recurrence (n = 40)
No change ER status 36 36
ER change Pos → neg 2 2
Neg → pos 2 2
No change PR status 35 37
PR change Pos → neg 2 2
Neg → pos 3 1
No change HER2 status 35 38
HER2 change Pos → neg 1 0
Neg → pos 4 2
  1. Changes were seen in 17 patients (some patients had more than 1 biomarker changed)